Bisantrene

Drug Profile

Bisantrene

Alternative Names: CL-216942; Cyabin; NSC-337766; Orange Crush; UPI-928; Zantrene

Latest Information Update: 01 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wyeth Pharmaceuticals
  • Developer Race Oncology; Wyeth Pharmaceuticals
  • Class Aldehydes; Anthracenes; Antineoplastics; Cytostatic antibiotics; Hydrazones; Imidazoles; Small molecules
  • Mechanism of Action DNA modulators; Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase Unknown Acute myeloid leukaemia; Cancer

Most Recent Events

  • 01 Jun 2017 Investigation is underway for Acute myeloid leukaemia and Cancer (Race Oncology website, June 2017)
  • 01 Jun 2017 Race Oncology intends to refile an IND application in USA for Acute myeloid leukaemia (Race Oncology website, June 2017)
  • 18 Feb 2014 Investigation in Acute myeloid leukaemia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top